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Dynamic contrast-enhanced MR imaging: study of inter-software 
accuracy and reproducibility using simulated and clinical data 
Abstract 
Purpose. To test the reproducibility and accuracy of pharmacokinetic parameter 
measurements on five analysis software packages (SPs) for dynamic contrast-enhanced 
magnetic resonance (DCE-MR) imaging, using simulated and clinical data. 
Materials and Methods. This retrospective study was institutional review board approved. 
Simulated tissues consisted of pixel clusters of calculated dynamic signal changes for 
combinations of Tofts model pharmacokinetic parameters (volume transfer constant [Ktrans], 
extravascular extracellular volume fraction [ve]), longitudinal relaxation time (T1). The 
clinical group comprised 27 patients treated for rectal cancer, with 36 3T DCE-MR scans 
performed between November 2012 and February 2014, including dual-flip-angle T1 mapping 
and a dynamic post-contrast T1-weighted, three-dimensional spoiled gradient-echo sequence. 
The clinical and simulated images were postprocessed with five SPs to measure Ktrans, ve and 
the initial area under the gadolinium curve (iAUGC). Modified Bland-Altman analysis was 
conducted, intraclass correlation coefficients and within-subject coefficients of variation were 
calculated. 
Results. Thirty one examinations from 23 patients were of sufficient technical quality and 
post-processed. Measurement errors were observed on the simulated data for all the 
pharmacokinetic parameters and SPs, with a bias ranging from -0.19 min-1 to 0.09 min-1 for 
Ktrans, -0.15 to 0.01 for ve, and -0.65 to 1.66 mmol.L-1.min for iAUGC. The intraclass 
correlation coefficient between SPs revealed moderate agreement for the simulated data 
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(Ktrans: 0.50; ve: 0.67; iAUGC: 0.77) and very poor agreement for the clinical data (Ktrans: 
0.10; ve: 0.16; iAUGC: 0.21). 
Conclusion. Significant errors were found in the calculated DCE-MR imaging 
pharmacokinetic parameters for the perfusion analysis SPs, resulting in poor inter-software 
reproducibility. 
Keywords 
DCE-MRI, quantitative parameters, Tofts model, inter-software variability, simulated images, 
rectal cancer  
 
3 
 
INTRODUCTION 
As a non-invasive technique providing information on tumor microcirculation, T1-weighted 
dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging has been investigated 
in various clinical applications and perfusion parameters recognized as potential biomarkers 
of early therapeutic response (1–3). Their value has notably been reported in the assessment 
of locally advanced rectal cancer response to chemo-radiotherapy (4–8). 
In order to establish a quantitative analysis of DCE-MRI acquisitions, Tofts and Kermode 
proposed a one-compartment perfused tissue model (9) that has become  standard (10). This 
model relates the MR signal measured in the tissue of interest over time to two 
pharmacokinetic parameters: a volume transfer constant Ktrans (min-1) and an extravascular 
extracellular volume fraction ve. Additionally, a rate constant kep corresponds to the ratio 
Ktrans/ve. (11). Another common DCE-MR imaging-derived parameter is the initial area under 
the gadolinium curve (iAUGC, mmol.L-1.min). This is a model free, semi-quantitative 
approach that also requires conversion of voxel signal intensity to gadolinium concentration 
(12). 
However, these quantitative methods can be affected by many sources of variation, including 
the strength and uniformity of the main static magnetic field (B0) and the radiofrequency field 
(B1), the chosen sequence (13), the temporal resolution (14), the pre-injection T1 relaxation 
time (T1,0) calculation (15), the estimation of the arterial input function (AIF) (16), and the 
region of interest (ROI) selection in the tumor (17). These variations may compromise 
inclusion of DCE-MR imaging in multicenter clinical trials and clinical practice (18). 
 
Literature reporting the impact of variations on the analysis of DCE-MR imaging due to 
software packages (SPs) is rare. Heye et al. showed considerable variability in 
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pharmacokinetic parameters between four perfusion analysis SPs on uterine fibroid data 
although additional variation may have been introduced by the use of two ROI methods and 
five observers (19). Moreover, the "true" pharmacokinetic parameters in clinical data are 
unknown because they are composite parameters with no direct physiological, histological or 
immunohistochemical equivalent (20). Producing simulated data with a known "ground truth" 
is therefore of value as it could be used to investigate accuracy among analysis SPs. 
The purpose of this study was to test the reproducibility and accuracy of pharmacokinetic 
parameter measurements on five analysis SPs for DCE-MR imaging, using both simulated 
and clinical data. 
This study was designed to test the hypothesis that analysis SPs do not cause variation or bias 
in Tofts model and semi-quantitative pharmacokinetic parameter measurements. 
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MATERIALS AND METHODS 
Institutional review board approval was obtained for this ancillary study of the GRECCAR 4 
trial (ClinicalTrials.gov identifier NCT0133709). 
Subjects and Perfusion Acquisition 
Twenty-seven consecutive patients (22 males, 5 females, mean age 62 years, range 31-82), 
screened in our institution for the GRECCAR 4 study investigating early response to 
chemotherapy in locally advanced rectal cancer, were included in this ancillary study. The 
main inclusion criteria were a histologically proven rectal adenocarcinoma and extramural 
extension on initial MR imaging. Thirty-six MR acquisitions (27 before treatment, 9 after 
chemotherapy) were performed between November 2012 and February 2014 on a 3T whole-
body system (Magnetom Verio, Siemens Healthcare, Erlangen, Germany). DCE-MR imaging 
consisted of a dynamic pre- and post-contrast T1-weighted, three-dimensional spoiled 
gradient-echo sequence (Volume Interpolated Breath-hold Examination, VIBE) whose 
parameters were: matrix 192x192, field of view 240x240 mm!, slice width 3 mm, repetition 
time (TR) 4.1 ms, echo time (TE) 1.4 ms, flip angle 15°, 24 slices, temporal resolution of 5.2 
s for an acquisition time of 3.5, 4.5 or 6 minutes, i.e. respectively 40, 52 or 70 dynamics. A 
bolus of gadolinium-DOTA (0.1 mmol/kg, Dotarem; Guerbet, Villepinte, France) was 
injected into an antecubital vein. In addition, dual-flip-angle (2° and 15°) pre-contrast T1 
mapping was performed. All data were stored in a research-dedicated server and could be 
retrieved retrospectively. On each examination, the slice on which the tumor section was the 
largest and most easily identifiable was selected by a radiologist (L.B., 4th-year radiology 
resident). A region of interest was drawn around all the tumor section on this slice, verified by 
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a  radiologist with 7 years of experience in rectal cancer evaluation (V.B.) and saved in the 
research-dedicated server. 
The generation of cross-vendor clinical and simulated evaluation data is illustrated in Figure 1 
and detailed below. 
Generation of Cross-vendor Evaluation Data 
Some SPs provided by MR scanner vendors do not allow analysis of DCE-MR images 
acquired on the scanners of rival vendors. To overcome this limitation, additional DCE-MRI 
acquisitions were performed on a General Electric Signa 1.5T (GE Healthcare, Milwaukee, 
WI) and a Philips Ingenia 3T scanner (Philips Healthcare, Best, the Netherlands) using a 
physical phantom (water container). The purpose of these new acquisitions was only to 
substitute these images with clinical images obtained on the 3T Verio system. Acquisition 
parameters were standardized to obtain the same spatial and temporal resolutions, TR, TE, 
flip angle, and slice thickness as on the reference Verio scan. In cases where the parameters 
could not be adjusted during the acquisition (e.g. B0 magnetic field strength) the DICOM 
header was edited with a batch DICOM metadata editor (DicomBrowser v 1.5.2, K. Archie, 
Neuroinformatics Research Group, 2012). 
A Mathematica-based software (Wolfram Research Inc., version 8.0.1.0, Champaign, IL) was 
developed to substitute phantom images acquired on the Signa and Ingenia systems with 
clinical images acquired on the Verio scanner, without changing the Dicom header. 
Generation of Simulated Data 
Simulated data were created in order to test the accuracy of each SP. We adapted a program 
written by D. Barboriak et al. (21) that ran in JSim, an open-source modeling system (22). 
This program simulated the Tofts model as it follows: 
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where Ctis is the concentration of contrast agent in the simulated tissue and Cp is the 
concentration in the blood plasma approximated by the arterial input function (9, 14). The 
variation of longitudinal relaxation time T1 of the simulated tissue or plasma due to the 
contrast media is as follows: 
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where C is the concentration of contrast media, r1 its longitudinal relaxivity and T1,0 the 
baseline T1 (before injection of the contrast media) (11). 
The program also simulated the spoiled gradient-echo MR sequence signal S corresponding to 
the simulated tissue:  
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where TR denotes the repetition time, " is the flip angle, and S0 denotes the equilibrium 
magnetization holding to the assumption that TE < T2* (23).  
The longitudinal relaxivity r1 of the contrast media was set to 3.9 mmol-1.s-1 (r1 relaxivity at 
37°C and 3T of DotaremTM in human plasma) (24), the blood longitudinal time of relaxation 
T1,0 to 1.6 s (25). 
Eighteen theoretical DCE-MR tissue signal curves were generated using different 
combinations of Ktrans (0.2, 0.4, 0.6 min-1), ve (0.2, 0.4, 0.6) and baseline longitudinal 
relaxation time T1,0 (800, 1000 ms). A population arterial input function was used for the 
simulation (21) and saved as a nineteenth signal curve, constituting the signal of a simulated 
artery voxel.  
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We developed a second Mathematica-based software to convert these curves into pixel 
clusters for three Gaussian noise levels (zero, mild [1% standard deviation] and strong [10% 
standard deviation]) and insert them into DICOM dynamic images (Figure 1b). Pixel clusters 
of a theoretical signal corresponding to the T1,0 of the tissues were also inserted into variable 
flip angle sequences. 
Perfusion Data Postprocessing 
The DCE-MR imaging postprocessing SPs evaluated in this study included three proprietary 
SPs (Table 1): syngo.MR Tissue 4D v.40A (Siemens Healthcare, Erlangen, Germany) [A], 
Advantage Windows GenIQ v.11.3 (GE Healthcare, Milwaukee, WI) [B], IntelliSpace Portal 
T1 Permeability v.6.0.1 (Philips Healthcare, Best, the Netherlands) [C]; and two academic 
plugins running in OsiriX (v.5.8.1, University Hospital of Geneva, Switzerland (26)): DCE 
Tool (v.2.0, K. Sung, UCLA, http://kyungs.bol.ucla.edu) [D] and UMM perfusion (v.1.5.1, F. 
Zöllner et al., University of Mannheim, Germany (27)) [E]. The DCE-MRI examinations with 
clinical images and those with simulated inserted data were transferred to each SP. One 
unblinded observer (L.B.) measured pharmacokinetic parameters on each SP, with the 
following approach regarding software options: 
-! use of the Tofts model (or, if unavailable, the extended Tofts model that also 
calculates vp, the plasmatic volume fraction) 
-! use of a patient-based AIF was preferred if available: an ROI was drawn in the left 
common femoral artery when postprocessing clinical data and in the simulated artery 
voxels when analyzing simulated data; 
-! if the time to peak was not automatically determined, the same value was input into 
each SP for each patient; 
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-! if the software did not incorporate T1,0 mapping but required a reference value 
corresponding to the tissue of interest the "Soft tissue" value (900 ms) was input; 
-! the iAUGC was set to the area under the gadolinium curve for 60 seconds after the 
bolus peak; 
-! no motion correction was applied. 
Parametric maps of Ktrans, ve, kep and iAUGC were exported and transferred to a centralized 
database. Sets of previously saved ROIs were applied to each parametric map in order to 
avoid measurement variability due to ROI positioning (28). 
Validation of the image data manipulation 
Extensive software manipulation of the image data was necessary so the same datasets could 
be evaluated with SPs from different vendors. To confirm that this manipulation was valid 
and did not introduce variability of its own, the original set of images acquired from one 
patient on the Verio scanner and the examinations acquired on the Signa and Ingenia systems 
in which the Verio images had been inserted were post processed with the same cross 
platform SP (DCE Tool). Same values of Ktrans, ve, kep and iAUGC were obtained for the three 
sets of images. 
Statistical Analysis 
Statistical analyses were performed using PASW Statistics (v.19.0, SPSS, Chicago, IL). 
Simulated Data 
A Bland-Altman analysis was conducted, measuring the difference between the value of a 
parameter measured by an SP and its simulated "true" value (29). Bias and dispersion 
correspond to the average and standard deviation of these differences, respectively. Intraclass 
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correlation coefficients (ICCs) and their 95% confidence intervals were calculated to 
determine the absolute agreement of pharmacokinetic parameter output among SPs. 
Clinical Data 
A Bland-Altman analysis was conducted, measuring the difference between the value of a 
parameter measured by SP X and the one measured by SP Y. ICCs were also calculated, and 
the test-retest root mean square coefficient of variation method (30) was applied to obtain the 
within-subject coefficient of variation for a pairwise comparison of all SP combinations. 
Ratio tumor / simulated reference tissue!
For each patient and each software package, the ratio between the pharmacokinetic 
parameters extracted from the ROI drawn over the tumor and those extracted from the ROI 
drawn over one simulated tissue (Ktrans = 0.4, ve = 0.4, T1,0 = 1000 ms, no noise), 
constituting a reference tissue, was calculated. Then, intraclass correlation coefficients for 
each pharmacokinetic parameter ratio among the different SPs were calculated. 
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RESULTS 
Simulated Data 
Fifty-four pixel clusters, corresponding to 18 combinations of Ktrans/ve/T1,0 values at three 
noise levels, were successfully fed into the dynamic MR images acquired on the three 
scanners and processed with the five SPs. The iAUGC of simulated tissues was in the range of 
14.8-44.5 mmol.L-1.min (mean 27.2 mmol.L-1.min, standard derivation 9.5 mmol.L-1.min). 
All measurements are provided in Appendix 1 and graphically plotted in Figure 2. Details of 
all statistical tests are given in the tables and figures. The most significant results are reported 
below. 
Bland-Altman Analysis 
A graphical representation of the Bland-Altman analysis is given in Figure 3, illustrating the 
accuracy of SPs for measuring the pharmacokinetic parameters. SPs A, B and D tended to 
underestimate Ktrans (bias: -0.13, -0.05 and -0.19 min-1, respectively), especially for high Ktrans 
values, whereas SPs C and E slightly overestimated it (bias: 0.03 and 0.09 min-1, 
respectively). SPs A, D and E underestimated ve (bias: -0.10, -0.13 and -0.15 min-1, 
respectively) and there was a wide dispersion of values measured by all the SPs (range 0.03-
0.8). SPs A and D measured iAUGC accurately but there was a wide dispersion of values 
measured by SPs B and C (5.05 and 8.17 mmol.L-1.min, respectively). 
Correlation Analysis 
The ICCs for testing absolute agreement between SPs in terms of pharmacokinetic parameters 
are given in Table 2, reflecting inter-software reproducibility. ICCs ranged from 0.50 for 
Ktrans to 0.77 for iAUGC. Subanalyses of repeatability considering potential sources of 
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variation among the SPs (excluding the SPs applying a different physiological model than 
Tofts model, not allowing for variable T1 mapping, or using a population based arterial input 
function) did not show significantly different values. 
The measurements on noiseless, low-noise and high-noise image sets were very similar, with 
an intraclass correlation coefficient between the calculated pharmacokinetic parameters at 
different levels of noise equal to 0.99. 
Clinical Data 
Five examinations (from four patients) were rejected: two of them because the cancer 
involved the anal canal, one due to an error in the slice orientation of the DCE-MR 
acquisition, and two due to severe artifacts caused by hip prostheses. Thirty one examinations 
were thus post processed. Among them, four could not be processed by SP C due to errors in 
variable flip angle sequences positioning. Mean tumor size was 6.8 cm!, ranging from 1.9 to 
24.4 cm!, and mean tumor T1,0 measured by the DCE Tool was 1201 ms, ranging from 423 to 
2280 ms. All measurements are provided in Appendix 2 and graphically plotted in Figure 4. 
Bland-Altman Analysis 
The Bland-Altman plots in Figure 5 show the differences in agreement between SPs. 
Dispersion was significant in all comparisons for all the pharmacokinetic parameters. Ktrans 
values returned by SP A were lower than values returned by all the other SPs, whereas all 
parameters values returned by SP B were higher than those returned by other SPs, except for 
Ktrans values when compared to SP E. Concerning the iAUGC measurements, the best 
agreement was observed between SPs A and D (bias: -3.48 mmol.L-1.min, dispersion: 7.69 
mmol.L-1.min). 
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Correlation Analysis 
The ICCs (Table 2) showed very poor agreement between SPs for all the pharmacokinetic 
parameters concerning clinical data, ranging from 0.10 for Ktrans to 0.21 for iAUGC.  
Subanalyses based on the SPs features did not show significantly better reproducibility, as for 
the ratios between the pharmacokinetic parameters extracted from the ROI drawn over the 
tumor and those extracted from a reference simulated tissue. 
Variation Analysis 
Within-subject coefficients of variation for all SP comparisons (Table 3) were always above 
0.20, except when comparing the iAUGC measurements provided by SPs A and D (0.19). 
They ranged from 0.40 to 0.88 for Ktrans, 0.27 to 0.47 for ve, 0.35 to 0.92 for kep, and 0.19 to 
0.76 for iAUGC. 
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DISCUSSION 
Our results yielded significant errors in pharmacokinetic measurements for all the perfusion 
analysis SPs when postprocessing simulated data, leading to substantial inter-software 
variability. Inter-SP reproducibility was worse when dealing with clinical data. 
 
The within-subject variation across SPs found in our study, ranging from 40% to 88% for 
Ktrans, was higher than the upper limit of 20% which is the goal of current quantitative 
imaging initiatives (18). It exceeded the 40% Ktrans decrease between pre- and post-
chemoradiotherapy found by Kim et al. to be associated with rectal tumor downstaging when 
using a single perfusion analysis SP (5). Considering that the  difference between mean Ktrans 
values after chemotherapy among patients with or without complete pathological response is 
about 0.3 min-1, according to Gollub et al. (4), the limits of agreement observed in our study 
are considerably wider and therefore a potential source of error when assessing patient 
prognosis. 
 
A large proportion of the observed variation may be explained by the different methods of T1,0 
relaxation time estimation. Some SPs computed parametric maps from T1-weighted variable 
flip-angle sequences whereas others used reference values from the literature or requested 
user input. Applying set T1,0 times across an entire heterogeneous lesion including areas of 
necrosis is a potential source of error (31). The T1,0 values measured in the clinical lesions had 
a much wider range than the 800 ms and 1000 ms values used in our simulated data, which 
were closer to the soft tissue reference value of 900 ms (25). This wide spectrum of T1,0 
values in the tumor, whether real or overestimated by the variable flip-angle method of 
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calculation, could provide an initial explanation for the greater variability seen in the 
pharmacokinetic parameters calculated from clinical data as compared to the simulated data. 
 
Another source of variation may be the arterial input function. Most SPs proposed a patient-
based AIF, asking the user to draw an ROI in an artery on the dynamic acquisition, whereas 
SP A only used a population-based AIF. Vascular peak characterization was automatic in two 
SPs and user-defined in the other SPs. This should mainly affect calculation of Ktrans, which 
reflects the earlier phases of the enhancement curve whereas ve correlates with the later phases 
(16), and could explain the greater variability of Ktrans as compared to ve in our measurements. 
Lastly, although this information was not always available in the SP documentation, it is 
probable that their curve-fitting algorithms were different, leading to differences in 
pharmacokinetic parameter output (32). 
 
The iAUGC measurement errors for SP C are surprising despite calculation of a parametric 
T1,0-map. The only source of error should arise from signal conversion to gadolinium 
concentration. Our theory is that this software does not integrate the measured data curve but 
its fit according to the Tofts model. Errors in curve adjustment according to Ktrans and ve could 
therefore bias calculation of iAUGC. 
 
Heye et al. previously showed considerable variability for DCE-MR imaging pharmacokinetic 
parameter computation among SP [A] and four cross-platform perfusion analysis SPs on 
clinical data (19). Huang et al. also showed a wide variability in pharmacokinetic parameters 
between between several multicentric in-house SPs on breast cancer data (33). Our 
comparison of the three main MR vendor SPs confirmed this lack of reproducibility and our 
results on simulated data quantify the measurement errors of each SP. 
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Using the same simulation tool but with lower Ktrans values, Cron et al. observed a high 
percentage of unphysical values when comparing the reaction of three DCE-MR analysis SPs 
to increasing noise levels (34).This study re-enforces the Quantitative Imaging Biomarkers 
Alliance profile recommendations that a single SP should be used for any longitudinal study 
or any static evaluation across a given population of patients (18). 
This study had limitations. Concerning the simulated data, the choice of Ktrans values was 
partly empirical, since average measurements in the literature dealing with rectal cancer 
ranged from 0.2 to 2.1 min-1 (4, 5, 7). We chose lower values reflecting our clinical practice 
and associated with physiological enhancement curves. We considered that 1026 
measurements on simulated data were sufficient to achieve statistical power but more 
combinations of pharmacokinetic parameters could have been used.  
We could have used a faster temporal resolution in our simulated data, but this choice requires 
acquiring fewer slices, which is a limiting factor in a clinical context because it implies a 
smaller coverage of the tumor. Moreover, although the technical parameters of the DCE MR 
sequence were suboptimal, they were the same for each postprocessing SP and thus cannot be 
held responsible for the variability we observed. 
Only one unblinded observer evaluated the postprocessing of simulated and clinical 
acquisitions, thus eliminating another measurement variability factor.  
Also, an additional source of variability concerning clinical data may have been the organ of 
interest, i.e. rectal tumors, which can be affected by technical difficulties such as peristaltism. 
Nevertheless, the technique we used was approved by several authors (4–8) and concerns 
pharmacokinetic measurement reproducibility.  
Inability to access the source code of commercial SPs prevented any automation in the 
postprocessing process, possibly resulting in additional variability due to the user, but this 
reflected clinical practice. 
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In conclusion, there are significant errors in calculated DCE-MR imaging pharmacokinetic 
parameters (Ktrans, ve, iAUGC) among perfusion analysis SPs, resulting in poor inter-software 
reproducibility. There is a need for standardization to enable the use of DCE-MR imaging as a 
quantitative biomarker in multicenter trials and clinical practice. For now, a single SP should 
be used in a given study, in agreement with international recommandations,and absolute 
values of pharmacokinetic parameters provided in the literature should be viewed with 
caution. 
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ABBREVIATIONS 
AIF = arterial input function 
DCE = dynamic contrast-enhanced 
DICOM = digital imaging and communications in medicine 
iAUGC = initial area under the gadolinium curve 
ICC = intraclass correlation coefficient 
Ktrans = volume transfer constant 
ROI = region of interest 
SP = software package 
ve = extravascular extracellular volume fraction 
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TABLES!
!"#$%&'(&!"#$%&'"(")*+(#,*#),%-.%/&01!2%34"5#$5%6-,*7(-)+,,#$5%86,&
Characteristics Tissue 4D [A] GenIQ [B] T1 permeability [C] DCE Tool [D] UMM perfusion [E] 
Developer Siemens General Electric Philips K Sung, UCLA 
F Zöllner, G Weisser, 
Mannheim University 
Platform Syngo Advantage Windows IntelliSpace Portal OsiriX OsiriX 
License Proprietary Proprietary Proprietary Free Open source 
Pharmacokinetic model Tofts Tofts, extended Tofts Extended Tofts Tofts, extended Tofts 
Tofts, extended Tofts,  
2 compartment exchange,  
2 compartment filtration,  
2 compartment uptake 
T1 relaxation time estimation 
Variable flip angle 
map or user input 
Reference value 
according to 
anatomical 
localization 
Variable flip angle 
map 
Variable flip angle 
map or user input 
None 
Arterial Input Function Population based 
Population or patient 
based 
Population or patient 
based 
Population or patient 
based 
Population or patient 
based 
Time to peak measurement User input Automatic Automatic User input User input 
Motion correction and registration Possible Possible No No No 
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!
!"#$%&'(&!""#$%&$'(#%)*+,$'-&,,.,/+$0,+1,,/$23#$4%&$356&.67%89/,+97$36&6.,+,&#$
Pharmacokinetic parameter Simulated Tissues  Clinical Data 
SP type ICC 95% CI  ICC 95% CI 
Ktrans      
All 0.50 0.23 – 0.70  0.10 0.01 – 0.25 
SPs applying Tofts model (excluding [C]) 0.43 0.14 – 0.65  0.12 0 – 0.29 
SPs allowing for variable T1 mapping ([A],[C], [D]) 0.47 0.04 – 0.74  0.10 -0.6 – 0.33 
SPs with patient based arterial input function (excluding [A]) 0.51 0.19 – 0.73  0.13 0 – 0.32 
All - ratio tumor / simulated reference tissue    0.11 0.02 – 0.27 
ve      
All 0.67 0.38 – 0.82  0.16 0.04 – 0.35 
SPs applying Tofts model (excluding [C]) 0.64 0.30 – 0.81  0.23 0.07 – 0.43 
SPs allowing for variable T1 mapping ([A],[C], [D]) 0.76 0.22 – 0.91  0.21 -0.01 – 0.47 
SPs with patient based arterial input function (excluding [A]) 0.63 0.28 – 0.81  0.14 0 – 0.35 
All - ratio tumor / simulated reference tissue    0.14 0.03 – 0.30 
kep      
All 0.55 0.29 – 0.73  0.11 0.01 – 0.28 
SPs applying Tofts model (excluding [C]) 0.46 0.17 – 0.67  0.12 0 – 0.28 
SPs allowing for variable T1 mapping ([A],[C], [D]) 0.82 0.57 – 0.91  0.13 -0.03 – 0.35 
SPs with patient based arterial input function (excluding [A]) 0.55 0.23 – 0.75  0.15 0.01 – 0.34 
All - ratio tumor / simulated reference tissue    0.13 0.02 – 0.29 
iAUGC      
All 0.77 0.69 – 0.85  0.21 0.02 – 0.44 
SPs applying Tofts model (excluding [C]) 0.90 0.84 – 0.94  0.27 0.01 – 0.53 
SPs allowing for variable T1 mapping ([A],[C], [D]) 0.77 0.66 – 0.85  0.44 0.12 – 0.69 
SPs with patient based arterial input function (excluding [A] 0.72 0.61 – 0.82  0.16 -0.02 – 0.41 
All - ratio tumor / simulated reference tissue    0.20 0.03 – 0.42 
      
ICC = intraclass correlation coefficient; CI = confidence interval; SPs = software packages 
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!)*+,&-(&:9+59/;2*(<,7+$"%,==979,/+#$%=$>6&96+9%/$=%&$'))$23$
"%.?6&9#%/#&
 Ktrans ve kep iAUGC 
A vs. B 0.82 0.37 0.78 0.49 
A vs. C 0.54 0.37 0.58 0.44 
A vs. D 0.63 0.29 0.69 0.19 
A vs. E 0.88 0.27 0.92 - 
B vs. C 0.67 0.47 0.53 0.76 
B vs. D 0.55 0.42 0.35 0.47 
B vs. E 0.40 0.28 0.45 - 
C vs. D 0.63 0.43 0.46 0.49 
C vs. E 0.75 0.31 0.69 - 
D vs. E 0.57 0.32 0.52 - 
A: Tissue 4D; B: GenIQ; C: T1 permeability; D: DCE Tool; E: UMM perfusion 
-: not available (iAUGC calculation is not available in UMM perfusion) 
The test-retest root mean square coefficient of variation method was applied to 
obtain the within-subject coefficient of variation for a pairwise comparison of all 
SP combinations 
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FIGURE LEGENDS 
Fig. 1: Diagram of the process of software packages (SPs) comparison with clinical images 
and simulated data. Phantom images acquired on the GE and Philips scanners were 
substituted with clinical dynamic images acquired on the Siemens scanner, without changing 
the DICOM headers.  Moreover, the banners with simulated pixel clusters were inserted into 
the dynamic images acquired on each scanner; the central cluster corresponds to the simulated 
artery, the other eighteen correspond to simulated tissues with different Ktrans, ve and T1,0 
combinations. 
Fig. 2: Box plots of simulated tissue pharmacokinetic parameters according to perfusion 
analysis SPs (light gray) compared to their “true” simulated values (dark gray). The top and 
bottom box edges represent the 25th and 75th percentiles, respectively; horizontal central 
lines represent the median values; top and bottom whiskers represent the 10th and 90th 
percentiles, respectively; circled points represent outliers. The results pertain to the entire set 
of reference values. 
Fig. 3: Bland-Altman analysis for simulated tissue pharmacokinetic parameters.  : bias 
(mean of the differences between the measured and simulated true value). Left and right ends 
of horizontal bars correspond to the lower and upper limits of agreement, respectively. The 
length of the horizontal bar is proportional to the dispersion. 
Fig. 4: Box plots of clinical data pharmacokinetic parameters according to perfusion analysis 
SPs. The top and bottom box edges represent the 25th and 75th percentiles, respectively; 
horizontal central lines represent the median values; top and bottom whiskers represent the 
10th and 90th percentiles, respectively; circled points represent outliers. 
Fig. 5: Bland-Altman analysis for clinical data pharmacokinetic parameters.  : bias (mean 
of the differences between the measurements taken on each lesion by two SPs). Left and right 
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ends of horizontal bars correspond to the lower and upper limits of agreement, respectively. 
The length of the horizontal bar is proportional to the dispersion. 
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